Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study
Descripción general
Resumen del artículo
This observational study suggests that lowering remnant cholesterol, as seen with new APOC3 and ANGPTL3 inhibitors, could reduce 10-year ASCVD risk by 2.7-4.1% in statin users and 1.4-2.1% in statin non-users with high remnant cholesterol. However, randomized controlled trials are needed to confirm these findings and establish causality.
Explícamelo como si tuviera cinco años
This study suggests that new cholesterol-lowering drugs could significantly reduce heart disease risk in people with high remnant cholesterol, but real-world trials are needed to confirm this.
Posibles conflictos de intereses
Anne Langsted received honoraria/consultancies from Amarin and Novartis and is currently employed by Novo Nordisk. Anette Varbo is also employed by Novo Nordisk. Børge G. Nordestgaard reports consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, and Marea.
Limitaciones identificadas
Explicación de la calificación
Strong methodology using a large cohort and registry data, but limitations inherent to observational studies prevent a higher rating. The declared conflicts of interest are also a concern.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →